Skip to content

Statistical Analysis Plan (SAP): A randomised, double-dummy, triple-blind, active placebo-controlled, parallel groups trial of LSD microdosing in patients with major depressive disorder (LSDDEP2)

Dimitri Daldegan-Bueno, Suresh Muthukumaraswamy, Alana Cavadino

Open MIND November 17, 2025 DOI: 10.17605/osf.io/tk739 (opens in new tab)

Relevant Not relevant

Study at a glance

AI-extracted from the abstract
Characteristics Statistical analysis plan Randomized Placebo-controlled Peer reviewed
Topics Depression LSD Microdosing
Key points The SAP specifies that analyses will assess the efficacy and safety of LSD (MB-22001) versus active placebo (caffeine), covering primary, secondary, and safety endpoints. No results are reported.

Abstract

The analyses described in this SAP will assess the efficacy and safety of LSD (MB-22001) in comparison with active placebo (caffeine). The analysis described cover those for the primary, secondary and safety endpoints described in the Protocol.

Related reading